Category - News

Developments

electroCore in research pact with Mass General

electroCore (NASDAQ:ECOR) is collaborating with Massachusetts General Hospital (MGH) in a neuroinflammation research program. Under the program, electroCore’s non-invasive vagus nerve stimulation (nVNS) will be studied...

August 9, 2018

Markets

Stifel cuts Corindus Vascular Robotics to hold; PT $1

Stifel downgraded Corindus Vascular Robotics (NYSE AMER:CVRS) to “hold” from “buy” and slashed its price target to $1 from $3 after “disappointing” first half results and now-lower 2018-2020 sales projects. Shares of...

August 8, 2018

Developments

Growing dysphagia incidence driving development of alternative modes of drug delivery

A new study published in the peer-reviewed journal, Dysphagia, suggests that the proportion of seniors with swallowing problems in the U.S. is expected to top 20% by 2030 from 15% currently. “Dysphagia has...

August 7, 2018

Markets

WB ups Vital Therapies to OP and FVE to $35 from $10

William Blair upgraded Vital Therapies (NASDAQ:VTL) to “outperform” from “market perform” and raised its fair value estimate to $35 from $10 ahead of top-line data from a pivotal study expected in September. The stock...

August 6, 2018

Markets

BTIG ups ViewRay PT to $14 from $10

BTIG raised its price target for ViewRay (NASDAQ:VRAY) to $14 from $10 after the stock pulled back from a recent climb to nearly $13. It closed at $11.05 on Aug. 3. “We felt the stock had overrun a bit to near $13 and...

August 6, 2018

Markets

Maxim cuts Immune Pharma to hold; removes PT

Maxim Group downgraded Immune Pharmaceuticals (OTCQB:IMNP) to “hold” from “buy” and removed its prior price target of $2 as the company continues to resolve its financing overhang. The stock closed at 13 cents on Aug. 3...

August 6, 2018

Developments

Titan Pharma, Molteni amend asset, supply, support agreement

Titan Pharmaceuticals (NASDAQ:TTNP) has entered into an amendment of an earlier asset purchase, supply and support agreement with L. Molteni & C. dei F.lli Alitti Società di Esercizio S.p.A., which allowed Molteni...

August 3, 2018

Markets

Ladenburg starts Allena Pharma at buy; PT $23

Ladenburg Thalmann initiated coverage of Allena Pharmaceuticals (NASDAQ:ALNA) with a “buy” rating and $23 price target. The stock closed at $10.49 on August 1. Allena’s developmental program is focused on the reduction...

August 2, 2018

Developments

Vasomune, AnGes in pact to target vascular leakage

Closely-held Vasomune Therapeutics and AnGes (Tokyo, TYO:4563) signed a global co-development agreement for the development and commercialization of therapeutics treating diseases associated with blood vessel...

July 31, 2018

Markets

HCW cuts SELLAS Life Sciences PT to $4 from $11

H.C. Wainwright slashed its price target for SELLAS Life Sciences (NASDAQ:SLS) to $4 from $11 after the company completed a $21.6-million offering of common shares, pre-funded warrants and warrants in July. The stock...

July 31, 2018

Category - News

Subscribe